In this study, participants will receive either rinatabart sesutecan or a treatment selected by their doctor, which may include medications such as doxorubicin or paclitaxel. These medications are administered through an IV infusion, a method where medicine is delivered directly into a vein through a small tube. The study aims to determine if the new drug works better than the standard options currently available for this condition.

During the course of the study, participants will undergo regular monitoring to track how the cancer responds to the medication and to observe any side effects. The researchers will look at how long the cancer remains stable without growing and the overall survival of the participants. This process involves continuous observation over several years to collect data on how the treatments affect the health and well-being of the individuals involved.

The purpose of the study is to find out if AZD8205 works better than standard chemotherapy in slowing down cancer growth and helping people live longer. The study will look at how long people live without their cancer getting worse and how long they survive overall. It will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long these responses last.

During the study, people will be randomly assigned to receive either AZD8205 given through a vein or chemotherapy chosen by their doctor. AZD8205 is given as an infusion, which means it is slowly dripped into a vein over a period of time. The study will continue for several years and will track how well the treatments work and what side effects occur. People will have regular check-ups and scans to see how their cancer is responding to treatment and to monitor their overall health and quality of life.

The medications will be administered in different ways – some as tablets taken by mouth, while others as solutions given through intravenous infusion (delivered directly into a vein). The treatment period may continue for up to 104 weeks, depending on how well patients respond to the therapy and any side effects they may experience.

This is known as an umbrella study, which means it includes several different groups of patients who will receive different combinations of treatments based on specific characteristics of their cancer. Some patients will receive a single medication, while others may receive a combination of treatments. The study will track how the cancer responds to these treatments and monitor the overall health of the participants throughout the treatment period.

The purpose of the study is to evaluate how well these medications work in treating the specified types of cancer. Participants in the study will receive either Durvalumab alone or a combination of Tremelimumab followed by Durvalumab. The study will observe how the cancer responds to these treatments over time. The trial will also look at the safety of the medications and any side effects that may occur. The study will involve regular visits to the clinic for treatment and monitoring, but specific details about the schedule are not provided here.

Throughout the study, researchers will also analyze the cancer cells at a very detailed level, known as single-cell profiling, to understand how they react to the treatment. This analysis will help identify any changes in the cancer cells and may provide insights into why some cells persist despite treatment. The study aims to gather information that could improve future cancer treatments and help understand the role of certain biomarkers, which are substances in the body that can indicate how well the treatment is working.

Participants in the study will be randomly assigned to receive either Selinexor or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased. The treatment will be administered orally, and the maximum treatment period is four months. The study will monitor the participants’ health and any changes in their condition over time.

The main goal of the study is to assess the progression-free survival, which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse. Other aspects being evaluated include the time to first and second subsequent therapies, overall survival, and the safety and tolerability of the treatment. Participants’ quality of life will also be assessed using specific questionnaires. The study aims to provide valuable information on the potential benefits of Selinexor for patients with advanced or recurrent endometrial cancer.